KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 1,163 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 1,163 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $15.00, for a total value of $17,445.00. Following the completion of the transaction, the insider directly owned 133,087 shares of the company’s stock, valued at approximately $1,996,305. The trade was a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded down $0.14 during mid-day trading on Friday, reaching $15.76. 113,039 shares of the company traded hands, compared to its average volume of 1,035,148. The company has a market capitalization of $796.42 million, a price-to-earnings ratio of -3.99 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The firm’s fifty day moving average is $15.52 and its two-hundred day moving average is $13.87.

Wall Street Analysts Forecast Growth

KALV has been the subject of several research reports. Needham & Company LLC upped their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright increased their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after buying an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $24,360,000. State Street Corp boosted its stake in shares of KalVista Pharmaceuticals by 21.3% in the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after purchasing an additional 336,195 shares during the period. Vestal Point Capital LP grew its stake in shares of KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.